Putting Patients First

Providing revolutionary tools to aid in the earlier diagnosis of Alzheimer’s Disease

LucentAD p-Tau 217

LucentAd p-Tau 217, Powered by Simoa^TM technology, is a non-invasive blood test that marks a major advance in helping to identify if a patient with mild cognitive impairment symptoms (MCI) is likely or unlikely to have amyloid plaques in the brain, a hallmark of Alzheimer’s Disease (AD).  

p-Tau 217 has emerged as a top performing blood-based biomarker for Alzheimer’s pathology, enabling clinical sensitivity and specificity in blood. Traditional confirmatory methods include positron emission tomography (PET) or lumbar puncture for cerebrospinal fluid (CSF), which are expensive, invasive, and lack wide availability. Lucent Diagnostics has evidence to support that the sensitivity and specificity of LucentAD p-Tau 217 is companiable to commonly used CSF for confirmation of amyloid pathology, without invasive collection or patient recovery time.

Exceptional Performance With Ease of Use

LucentAD p-Tau 217 test achieved an overall accuracy exceeding 90%, which meets the stringent requirements set forth in the most recent Alzheimer’s Association (AA) Workgroup Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease. Furthermore, the AA Workgroup criteria identifies p-Tau 217 as the only plasma biomarker appropriate for accurately diagnosing amyloid pathology. 

The LucentAD p-Tau 217 test is run in Lucent Diagnostics CLIA certified laboratory and is available in the US to medical providers, for their eligible patients. Blood samples are shipped, refrigerated or frozen, to the Lucent laboratory in packaging provided. The company plans to announce additional tests, aimed at improving the diagnosis and management of AD and other neurological disorders.

Patient & Caregiver Empowerment

Patient empowerment lies at the core of our mission. We understand the anxiety and uncertainty that Alzheimer’s Disease can bring to both patients and caregivers. Lucent Diagnostics is passionate about making a difference in the lives of patients and their families. We are committed to providing you with the knowledge and tools you need to make the most informed decisions about your health.

Affordable Testing

Lucent AD p-Tau 217 is intended for patients with mild cognitive impairment and/or who are undergoing cognitive evaluation. This test is new and is not currently covered by commercial insurance, Medicare or Medicaid. Lucent Diagnostics is currently pursing payer coverage. In the meantime, we will work with patients to provide testing within their financial means. Consult your healthcare provider to see if LucentAD p-Tau 217 is right for you or your loved one.

Take Action

Ask your healthcare provider if the LucentAD p-Tau 217 blood-test is right for you.

Click on the Patient Instructions Kit button below to print and share information about the LucentAD test with your healthcare provider.

Step 1

Your health care provider orders the LucentAD p-Tau 217 blood test and schedules a blood draw appointment.

Step 2

Your blood sample is sent to the Lucent Diagnostics laboratory for analysis.

Step 3

Your doctor receives the LucentAD p-Tau 217 test report and discusses the results with you.

Patient Instructions Kit

Learn More

Looking for more information to share with your provider? Please contact the Lucent Diagnostics Customer Service Team at 978.488.1869 or email customerservice@lucentdiagnostics.com

Contact Us to Order a Test

Disclaimer

The information provided on this website is for educational purposes only and should not be considered as medical advice. Please consult with your healthcare provider for personalized guidance and treatment options.

Disclaimer